Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

1Q18—the risk-capital roll continues

The biotech sector took in record amounts of venture capital last quarter—the largest amount of venture capital in a single quarter since data provider BioCentury started tracking it in 1994. Partnerships, debt and follow-on offerings were also all up, whereas funding from initial public offerings (IPOs) fell, especially outside the United States. Immuno-oncology continues to feature in major deals, with Celgene acquiring Juno, and Nektar signing a multibillion-dollar licensing deal with Bristol-Myers Squibb.

Stock market performance

Global biotech initial public offerings

Global biotech venture capital investment

Global biotech industry financing

Notable 1Q18 deals

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

DeFrancesco, L. 1Q18—the risk-capital roll continues. Nat Biotechnol 36, 487 (2018). https://doi.org/10.1038/nbt.4160

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.4160

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing